Because response to glucocorticoid therapy alone predicts overall outcomes for patients with B-ALL [2,3], enhancing GR activity is an attractive mechanism for improving outcomes, particularly in high-risk disease. This evidence concerns the gene NR3C1 and acute lymphoblastic leukemia.